CHWY vs ELAN: How Chewy and Elanco Animal Health Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CHWY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CHWY and ELAN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CHWY and ELAN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Chewy is the largest pure-play online retailer of pet products in the United States, selling pet food, treats, supplies, prescription medications, and other essentials, plus a growing set of pet-health services. The core of the model is Autoship, an auto-replenishment subscription that schedules recurring deliveries of food and supplies; Autoship accounts for roughly 83% of net sales, which gives Chewy unusually predictable, repeat-purchase revenue for a retailer. The company makes most of its money on product sales at retail-style gross margins, but it is steadily mixing in higher-margin revenue from Chewy Pharmacy, sponsored ads through its Chewy Ads retail-media network, and veterinary care. In fiscal 2025 (the year ended February 1, 2026) Chewy reported net sales of about $12.60 billion, up 6.2% (roughly 8.3% on a comparable 52-week basis), with around 21.3 million active customers and net sales per active customer near $600.

Full CHWY guide

Elanco Animal Health was spun out of Eli Lilly in 2018 and became one of the largest standalone animal health companies in the world after buying Bayer Animal Health in 2020. The business splits roughly into Pet Health (flea and tick parasiticides such as Credelio and Seresto, the dermatology drug Zenrelia, pain products such as Galliprant) and Farm Animal (cattle, poultry, swine and aqua-adjacent products including Rumensin, Experior and the methane-reducing feed additive Bovaer in the US). Revenue comes through veterinary clinics, distributors, retail and e-commerce channels, and from farm producers who buy on economics rather than sentiment, which makes the two halves behave quite differently across a cycle.

Full ELAN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CHWY drivers: Autoship makes the revenue sticky; Higher-margin businesses are the profit lever.
• ELAN drivers: The new pet blockbusters; Margin and leverage repair.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Chewy operates in a structurally low-margin retail business, so even with mix improvements its net margins sit in the low single digits and small cost or pricing shifts matter a lot. For ELAN, competition is the central risk: Zoetis is larger, better capitalized and defends the parasiticide and dermatology categories aggressively, and Merck, Boehringer Ingelheim and others are active in the same clinics.

Pick CHWY if you believe its drivers more; ELAN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CHWY and ELAN guides.

CHWY. Chewy is best read as a profitable but low-margin retailer that is trying to mix in higher-margin revenue, so watch the trend in gross margin and adjusted EBITDA margin more than headline sales growth. Because product sales dominate, net margins are thin (low single digits), and free cash flow is often a cleaner gauge of health than GAAP net income, which can be swung by share-based compensation and tax items. Active-customer growth and net sales per active customer show whether the base is expanding or just spending more. Since Chewy pays no dividend and reinvests in pharmacy, ads, and vet care while buying back stock, the valuation hinges on whether those higher-margin businesses scale fast enough to justify a growth multiple.

ELAN. At roughly $27 a share the stock trades near the low-to-mid 20s times the midpoint of 2026 adjusted EPS guidance, and closer to ~15x to ~16x enterprise value to adjusted EBITDA once the ~$3.2 billion of net debt is included. That is a discount to Zoetis on most multiples, which reflects the leverage and the slower legacy portfolio rather than a disagreement about the new launches. The shares have roughly doubled over the past year, so much of the easy re-rating from deeply-out-of-favor levels has already happened.

Headline figures (approximate, FY2025 results (year ended February 1, 2026) and Q1 FY2026 (ended May 3, 2026)): CHWY shows fy2025 net sales About $12.60 billion, up 6.2% (roughly 8.3% on a 52-week basis), fy2025 net income About $222.8 million, fy2025 adjusted ebitda About $719 million, up roughly 26%, fy2025 free cash flow Record of about $562 million; ELAN shows revenue (ttm) ~$4.9B, q2 2026 revenue ~$1.37B, up ~10% reported and ~8% organic constant currency, fy 2026 revenue guidance ~$5.09B to ~$5.14B, fy 2026 adjusted ebitda guidance ~$1.01B to ~$1.035B.

CHWY and ELAN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CHWY and ELAN exposure against your real portfolio. It is not an investment adviser.